---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-016231"
form_type: "8-K"
ticker: "RMD"
cik: "0000943819"
company_name: "RESMED INC"
filed_at: "2023-01-26T23:59:59+00:00"
generated_at: "2026-06-20T09:00:04.050295+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ResMed Q2 revenue up 16% to $1.03B, EPS $1.53; CEO Farrell appointed Board Chair

## Summary
- Revenue $1,033.7M (+16% YoY, +20% constant currency); GAAP EPS $1.53, non-GAAP $1.66.
- Gross margin contracted 30 bps to 56.1%; non-GAAP gross margin 56.8%.
- Mick Farrell, current CEO, named Board Chair; founder Peter Farrell becomes Chair Emeritus.
- Quarterly dividend $0.44/share declared, payable March 16, record date Feb 9.
- Closed acquisition of MEDIFOX DAN in Germany, expanding out-of-hospital SaaS business.

## SEC filing metadata
- accession: 0001193125-23-016231
- form_type: 8-K
- ticker: RMD
- cik: 0000943819
- company_name: RESMED INC
- filed_at: 2023-01-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/943819/000119312523016231/0001193125-23-016231-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/943819/000119312523016231/d369496d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-016231
- JSON: https://secwatch.observer/filing/0001193125-23-016231.json
- Plain text: https://secwatch.observer/filing/0001193125-23-016231.txt

## Key facts
- Earnings Releases
  RESMED INC reported the quarter ended December 31, 2022 results: revenue $ 1,033.7, net income $ 224.9, EPS $ 1.53.
  - Period: the quarter ended December 31, 2022
  - Revenue: $ 1,033.7
  - Net income: $ 224.9
  - EPS: $ 1.53
  - Result: reported results
  source text: Three Months Ended December 31, 2022 December 31, 2021 % Change Constant Currency (A) Revenue $ 1,033.7 $ 894.9 16 % 20 % Gross margin 56.1 % 56.4 % (1 ) Non-GAAP gross margin (B) 56.8 % 57.6 % (1 ) Selling, general, and administrative expenses 211.7 185.4 14 20 Research and development expenses 69.9 62.5 12 15 Income from operations 280.2 248.7 13 Non-GAAP income from operations (B) 305.5 267.7 14 Net income 224.9 201.8 11 Non-GAAP net income (B) 244.4 216.2 13 Diluted earnings per share $ 1.53 $ 1.37 12 Non-GAAP diluted earnings per share (B) $ 1.66 $ 1.47 13
  evidence_url: https://www.sec.gov/Archives/edgar/data/943819/000119312523016231/0001193125-23-016231-index.htm
- Executive change
  Michael J. 'Mick' Farrell was appointed as chair of the board of directors at RESMED INC.
  - Action: appointed
  - Role: chair of the board of directors
  source text: On January 25, 2023, our board of directors appointed Michael J. “Mick” Farrell as chair of our board of directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/943819/000119312523016231/0001193125-23-016231-index.htm
- Executive change
  Dr. Peter C. Farrell was appointed as chair emeritus at RESMED INC.
  - Action: appointed
  - Role: chair emeritus
  source text: In recognition of Dr. Farrell’s long and valuable service as chair, the board of directors appointed him to the new director position of chair emeritus, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/943819/000119312523016231/0001193125-23-016231-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.